Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg

被引：0
|
作者：
D. Cibula
U. Karck
H. G. Weidenhammer
J. Kunz
S. Alincic
J. Marr
机构：
[1] Charles University,Department of Obstetrics and Gynaecology, General Faculty Hospital
[2] University of Freiburg,Department of Obstetrics and Gynaecology
[3] Klarastr,undefined
[4] Hospital Zollikerberg,undefined
[5] Schering AG,undefined
[6] MDG G&A,undefined
来源：
Clinical Drug Investigation | 2006年 / 26卷
关键词：
Combine Oral Contraceptive; Contraceptive Efficacy; Drospirenone; Withdrawal Bleeding; Normal Menstruation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The purpose of this study was to assess the efficacy and safety of a new low-dose oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg (EE 20μg/drsp 3mg).
引用
收藏
页码：143 / 150
页数：7
相关论文
共 38 条
  • [31] A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg
    Mabrouk, Mohamed
    Solfrini, Serena
    Frasca, Clarissa
    Del Forno, Simona
    Montanari, Giulia
    Ferrini, Giulia
    Paradisi, Roberto
    Seracchioli, Renato
    GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (06) : 451 - 454
  • [32] Ethinyl estradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder
    Marr, Joachim
    Heinemann, Klaas
    Kunz, Michael
    Rapkin, Andrea
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2011, 113 (02) : 103 - 107
  • [33] Evaluation of the quality of life and sexual functioning of women using a 30-μg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive
    Skrzypulec, V.
    Drosdzol, A.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2008, 13 (01): : 49 - 57
  • [34] Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin® 24 Fe)
    Nakajima, Steven T.
    Archer, David F.
    Ellman, Herman
    CONTRACEPTION, 2007, 75 (01) : 16 - 22
  • [35] Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin
    Bachmann, Gloria
    Kopacz, Sharon
    PATIENT PREFERENCE AND ADHERENCE, 2009, 3 : 259 - 264
  • [36] The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle:: an observational study
    Fruzzetti, Franca
    Lello, Stefano
    Lazzarini, Veronica
    Fratta, Stefania
    Orru, Marisa
    Sorge, Roberto
    Minerba, Luigi
    Ricci, Cabiria
    Genazzani, Andrea Riccardo
    Melis, Glan Benedetto
    Paoletti, Anna Maria
    CONTRACEPTION, 2007, 75 (03) : 199 - 203
  • [37] A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 μg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight
    Endrikat, Jan
    Sandri, Mirella
    Gerlinger, Christoph
    Ruebig, Alexander
    Schmidt, Werner
    Fortier, Michel
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2007, 12 (03): : 220 - 228
  • [38] Conventional vs. Extended-Cycle Oral Contraceptives on the Quality of Sexual Life: Comparison between Two Regimens Containing 3 mg Drospirenone and 20 μg Ethinyl Estradiol
    Caruso, Salvatore
    Sareri, Marco Iraci
    Agnello, Carmela
    Romano, Mattea
    Lo Presti, Lucia
    Malandrino, Chiara
    Cianci, Antonio
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 (05): : 1478 - 1485
1234